Furthermore, through a series of screening and validation assays, we identified Mupirocin as a novel inhibitor of FTO, which showed synergistic effect of Mupirocin and Erastin or RSL3 on inhibiting the tumorigensis of CRC, which provides proof-of-concept evidence indicating the therapeutic potential of pharmacological targeting FTO plus with Erastin and RSL3 for treating CRC (Fig. S8i). Here, FTO is linked to colorectal carcinoma.